Objectives: Autoantibodies against myelin oligodendrocyte glycoprotein (MOG) are associated with the inflammatory demyelinating disease spectrum of CNS in children.

Materials –Methods: We retrospectively analyzed six  patients  who had been diagnosed as having anti-MOG antibody positive acquired CNS demyelinating disease at  Ege University  Child Neurology Divison.

Results: The age at diagnosis were between  3-13 years.  The most common complaints were headache, vision loss, diplopia, ataxia, cognitive problems, drowsiness, aphasia in order of frequency. Two patients were diagnosed with ON, two patients NMOSD, one patient ADEM and one patient was diagnosed with MDEM. The number of relapses ranged from 1 to 23, with follow up periods ranging from 1 to 15 years. Neuroimaging findings were   compatible with cerebral white matter, spinal cord, and optic nerve involvement. Their sera were positive for anti MOG antibody . On the other hand one patient with NMOSD  had antibodies  for  both AQP4 and MOG antigens.  All patients were given  intravenous pulse methylprednisolone therapy followed  oral steroids. Patients having relapsing courses were started either azathioprine or monthly IVIG for long-term treatment.

Conclusion: However the presence of anti-MOG antibody is an important marker for non-MS demyelinating disease,  relapses  are frequent during course of  the demyelinating disease related with anti MOG antibody. Unfortunately, there is no consensus in terms of  risk factors for relapse, treatment  protocols for relapses and long-term follow-up. Increasing the number of patients with anti MOG antibodies  will clarify our knowledge about this entity.